Market-Moving News for May 30th
$AI
$CADL
$ONMD
Computer Software: Prepackaged Software
Technology
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $AI alert in real time by email
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 5/30/2024 | $35.00 | Market Perform → Outperform | Northland Capital | |
| 11/21/2023 | $40.00 | Perform → Outperform | Oppenheimer | |
| 7/25/2023 | $40.00 | Market Perform | Northland Capital | |
| 6/29/2023 | Perform | Oppenheimer | ||
| 6/1/2023 | $24.00 → $50.00 | Neutral → Outperform | Wedbush | |
| 6/1/2023 | $30.00 | Buy → Neutral | DA Davidson | |
| 4/24/2023 | $14.00 | Peer Perform → Underperform | Wolfe Research | |
| 2/3/2023 | $30.00 | Buy | DA Davidson |
C3 AI (NYSE:AI), the Enterprise AI application software company, today announced it will issue its financial results for the fiscal second quarter, which ended October 31, 2024, following the close of the U.S. markets on Monday, December 9, 2024. C3 AI will host a conference call and webcast to discuss the financial results. The conference call will begin at 2:00 p.m. PST / 5:00 p.m. EST on December 9, 2024. Analysts and investors may participate in the question-and-answer session. Conference Call Details Date: Monday, December 9, 2024 Time: 2:00 p.m. Pacific Standard Time To access the conference call via a dial-in number and personalized PIN code, participants should register here: t
Continued Accelerating Revenue Growth C3.ai, Inc. ("C3 AI," "C3," or the "Company") (NYSE:AI), the Enterprise AI application software company, today announced financial results for its fiscal first quarter ended July 31, 2024. "We had a solid start to the fiscal year, with rising demand for Enterprise AI driving our sixth consecutive quarter of accelerating revenue growth," said Thomas M. Siebel, Chairman and CEO, C3 AI. "C3 AI is the original Enterprise AI company. Our unwavering commitment to solving the most challenging problems in the enterprise has led us to what we believe are the highest levels of customer satisfaction in the industry." Fiscal First Quarter 2025 Financial Highl
C3 AI (NYSE:AI), the Enterprise AI application software company, today announced it will issue its financial results for the fiscal first quarter, which ended July 31, 2024, following the close of the U.S. markets on Wednesday, September 4, 2024. C3 AI will host a conference call and webcast to discuss the financial results. The conference call will begin at 2:00 p.m. PDT / 5:00 p.m. EDT on September 4, 2024. Analysts and investors may participate in the question-and-answer session. Conference Call Details Date: Wednesday, September 4, 2024 Time: 2:00 p.m. Pacific Standard Time To access the conference call via a dial-in number and personalized PIN code, participants should regist
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - C3.ai, Inc. (0001577526) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
Northland Capital upgraded C3.ai from Market Perform to Outperform and set a new price target of $35.00
Oppenheimer upgraded C3.ai from Perform to Outperform and set a new price target of $40.00
Northland Capital initiated coverage of C3.ai with a rating of Market Perform and set a new price target of $40.00
AI-powered solutions to drive operational excellence across diverse industries C3 AI (NYSE:AI), the Enterprise AI application software company, and Capgemini, a global leader in business and technology transformation, today announced an expansion of their partnership. This partnership is designed to accelerate and enhance the delivery of Enterprise AI solutions across industries to help clients realize significant benefits including improved efficiency, productivity, and cost reduction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241120805270/en/ This partnership combines the power of C3 AI's Enterprise AI applications with
Technical integration, product development, joint sales and delivery Today at Microsoft Ignite, C3 AI (NYSE:AI), the Enterprise AI application software company, and Microsoft Corp. (NASDAQ:MSFT) announced a strategic alliance to accelerate the adoption of Enterprise AI on Microsoft Azure. The agreement marks a significant milestone in C3 AI and Microsoft's existing partnership, further combining C3 AI's Enterprise AI–native application software, including C3 Generative AI, with Azure's robust and expansive ecosystem to the benefit of enterprises globally. "C3 AI has pioneered Enterprise AI for over a decade, accelerated by collaboration with Microsoft to enable iconic organizations to s
On track for topline disease-free survival data from the phase 3 randomized controlled clinical trial of CAN-2409 in localized intermediate/high risk prostate cancer, expected in Q4 2024On track for topline progression-free survival data from the phase 2b randomized controlled clinical trial of CAN-2409 in the active surveillance population with localized low/intermediate risk prostate cancer, expected in Q4 2024Presented preclinical data on therapeutic potential of CAN-3110 in melanoma at the SITC 2024 Annual MeetingThe Company expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan to the end of Q1 2025 NEEDHAM, Mass., Nov. 14, 2024 (GLO
TSLANVDAAICRWDQQQWAYGOOGLAAPLAMZNLOTData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment
TSLACRWDNVDAWAYUPSAIGOOGLSPOTAMZNAAPLData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment
SC 13G/A - C3.ai, Inc. (0001577526) (Subject)
SC 13G - OneMedNet Corp (0001849380) (Subject)
SC 13G/A - C3.ai, Inc. (0001577526) (Subject)
NT 10-Q - OneMedNet Corp (0001849380) (Filer)
SCHEDULE 13G - C3.ai, Inc. (0001577526) (Subject)
10-Q - Candel Therapeutics, Inc. (0001841387) (Filer)
C3 AI (NYSE:AI), the Enterprise AI application software company, today announced that General (Ret.) John E. Hyten has been appointed to its board of directors, effective immediately. "General Hyten is a distinguished military leader who guided the U.S. military through periods of significant transformation," said Thomas M. Siebel, Chairman and CEO, C3 AI. "His deep understanding of the necessity of AI to modernize the defense sector along with his first-hand experience with government agencies are invaluable as we continue to assist our federal and intelligence communities to deploy enterprise AI at scale." As a board member, General Hyten will work with the board of directors and with C
MINNEAPOLIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Real World Data (RWD), has announced that Bob Golden has joined the OneMedNet Executive Team as Chief Financial Officer spearheading all aspects of the company's financial and accounting operations while continuing to serve as a member of the Board of Directors. Mr. Golden is a Certified Public Accountant with more than 40 years of experience. Mr. Golden has served as the Managing Partner of Cohen, Bender & Golden LLP since 2015, where he provides consulting, accounting and tax services to middle market businesses and owners. Mr. Golde
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro